TheWealthWeb

Invesco India Pharma and Healthcare Fund Regular Growth

Invesco Mutual FundEquity Schemes - Sectoral FundRegular · GrowthRisk: Very High

NAV ₹10.54 on 13 November 2026

AMFI name: Invesco India Pharma and Healthcare Fund - Regular Plan - Growth · Scheme code 154545

Since launch, a year
+34.24%
NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY HEALTHCARE INDEX TRICategory median
1M+15.57%+8.67%+8.25%
6M-+12.84%+9.28%
1Y-+38.92%+4.48%
3Y-+28.05%+15.37%
5Y--+13.85%

Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates. The scheme document names BSE Healthcare TRI, which we do not hold, so this is the closest NSE index.

Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Schemes - Sectoral Fund” category, up to 20 funds with clean data. Ranks are under “Rank among peers”.

Risk

From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.

Max drawdown
-11.50%
Worst fall from a peak, 3 years
Sortino ratio
2.33
Like Sharpe, counting only falls, 3 years
Alpha
+6.16%
Return a year beyond what beta explains, 3 years
Beta
0.99
1.00 moves in step with the benchmark, 3 years
Upside capture
104%
Share of the benchmark's rises captured, 3 years
Downside capture
99%
Share of the benchmark's falls taken (lower is better), 3 years

Rank among peers

Regular plans, Growth option, in AMFI's “Equity Schemes - Sectoral Fund” category. Each rank counts only the peers that have that figure.

Compare with Top Peers
3-Year Return Rank
-of 142
-
N/A
Q1
Q2
Q3
Q4
1-Year Return Rank
-of 233
-
N/A
Q1
Q2
Q3
Q4
Sharpe (Risk-Adjusted)
-of 232
-
N/A
Q1
Q2
Q3
Q4
Highest 3-year returns in the categoryRegular plans · Growth option
RankScheme Name3Y Return1Y ReturnSharpeDirect TERAUM
#1
Nippon India Mutual Fund
+46.52%+60.64%1.071.06%₹1,100 Cr
#2
HDFC Mutual Fund
+33.64%+20.34%1.070.89%₹11,128 Cr
#3
HDFC Mutual Fund
+31.28%+31.60%1.761.03%₹3,128 Cr
#4
SBI Mutual Fund
+25.42%+26.07%1.470.76%₹5,565 Cr
#5
HDFC Mutual Fund
+24.77%+10.10%1.091.10%₹1,997 Cr
#6
Mirae Asset Mutual Fund
+24.42%+27.89%1.28-₹3,458 Cr
#7
UTI Mutual Fund
+23.89%+22.00%1.311.35%₹1,399 Cr
#8
ICICI Prudential Mutual Fund
+22.73%+10.29%0.952.08%₹3,926 Cr
#-
Invesco India Pharma and Healthcare FundCurrent Fund
Invesco Mutual Fund
----₹111 Cr

Costs and fund facts

Exit load
Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax
Fund size (all plans)
₹111 CrAverage, quarter to September 2026
Benchmark
BSE Healthcare TRICompared here with NIFTY HEALTHCARE INDEX TRI
Allotment date
7 September 2026Scheme document
Type
An open ended equity scheme investing in Pharma, Healthcare and allied sectors
AMFI scheme code
154545

Fund manager

  • Aditya Khemanisince 07-Sep-2026

How each manager has done since taking over: fund manager scorecard.

Investment objective

To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 10 Sept 2026 to 13 Nov 2026
Total Invested3 mos
₹30,000
Units: 3,079.179
Current Portfolio Value
₹32,455
At latest recorded NAV
Total Profit
+₹2,455
+8.2% absolute return
SIP XIRR
105.82%
Annualised, money-weighted
Wealth CompositionProfit is 8% of total invested capital
Invested: ₹30,000Profit Generated: ₹2,455
Same SIP in the benchmark (NIFTY HEALTHCARE INDEX TRI)Same dates & amounts
Scheme SIP Valuation
₹32,455
105.8% XIRR
Benchmark SIP Valuation
₹5,56,767
25.8% XIRR
Fund minus benchmark
₹-5,24,312
Over 3 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

Invesco India Pharma and Healthcare Fund Regular Growth is a mutual fund scheme from Invesco Mutual Fund, listed by AMFI under “Equity Schemes - Sectoral Fund”. This page covers the Regular plan with the Growth option. Its NAV was ₹10.54 on 13 November 2026. The fund house rates its risk as “Very High” on the SEBI riskometer. Its average assets under management were ₹111 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Managed by Aditya Khemani. Its scheme summary document gives the allotment date as 7 September 2026.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.

Plans and options of this fund (4)

PlanOptionISINAMFI codeNAV
RegularThis pageGrowth-154545₹10.5413 Nov 2026
DirectGrowth-154547₹10.5813 Nov 2026
DirectIDCW-154546₹10.5813 Nov 2026
RegularIDCW-154544₹10.5413 Nov 2026